COVID‐19 associated EBV reactivation and effects of ganciclovir treatment

BACKGROUND: Systemic reactivation of Epstein–Barr virus (EBV) may occur in novel coronavirus disease 2019 (COVID‐19) caused by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). However, the clinical consequences of EBV reactivation remain uncertain. METHODS: In this retrospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Mei, Zhang, Sheng, Dong, Xuan, Sun, Wenqing, Deng, Yunfeng, Li, Wenzhe, Li, Ranran, Annane, Djillali, Wu, Zhixiong, Chen, Dechang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959425/
https://www.ncbi.nlm.nih.gov/pubmed/35349757
http://dx.doi.org/10.1002/iid3.597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959425/
https://www.ncbi.nlm.nih.gov/pubmed/35349757
http://dx.doi.org/10.1002/iid3.597

Ejemplares similares